The DOI matches its Crossref record; 402 of the 402 references it cites were found in a registry or an index.
Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs
Open accessAbstract
Nucleoside, nucleotide, and base analogs have been in the clinic for decades to treat both viral pathogens and neoplasms. More than 20% of patients on anticancer chemotherapy have been treated with one or more of these analogs. This review focuses on the chemical synthesis and biology of anticancer nucleoside, nucleotide, and base analogs that are FDA-approved and in clinical development since 2000. We highlight the cellular biology and clinical biology of analogs, drug resistance mechanisms, and compound specificity towards different cancer types. Furthermore, we explore analog syntheses as well as improved and scale-up syntheses. We conclude with a discussion on what might lie ahead for medicinal chemists, biologists, and physicians as they try to improve analog efficacy through prodrug strategies and drug combinations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ghoshal, K., Datta, J., Majumder, S., Bai, S., Kutay, H., Motiwala, T., & Jacob, S. T. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.11.4727-4741.2005 · Cited by 431
RetractedSiegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
(2012) · Hepatogastroenterology · doi:10.5754/hge12469 · Cited by 3,178
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Cellular differentiation, cytidine analogs and DNA methylation
Jones, P. A., & Taylor, S. M. (1980) · Cell · doi:10.1016/0092-8674(80)90237-8 · Cited by 1,831
Fluorinated pyrimidines, a new class of tumour-inhibitory compounds
HEIDELBERGER, C., CHAUDHURI, N. K., DANNEBERG, P., MOOREN, D., GRIESBACH, L., DUSCHINSKY, R., SCHNITZER, R. J., PLEVEN, E., & SCHEINER, J. (1957) · Nature · doi:10.1038/179663a0 · Cited by 1,603
MLL translocations, histone modifications and leukaemia stem-cell development
Krivtsov, A. V., & Armstrong, S. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2253 · Cited by 1,249
Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases
Jordheim, L. P., Durantel, D., Zoulim, F., & Dumontet, C. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4010 · Cited by 1,211
DNA methylation and gene silencing in cancer
Baylin, S. B. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0354 · Cited by 1,154
(2011) · Hepatogastroenterology · doi:10.5754/hge11069 · Cited by 1,140
Broad-Spectrum Antiviral Activity of Virazole: 1-β-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
Sidwell, R. W., Huffman, J. H., Khare, L., Allen, B., Witkowski, R., & Robins, K. (1972) · Science · doi:10.1126/science.177.4050.705 · Cited by 985
Clinical Pharmacology of 5-Fluorouracil
Diasio, R. B., & Harris, B. E. (1989) · Clinical Pharmacokinetics · doi:10.2165/00003088-198916040-00002 · Cited by 969
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine
Stresemann, C., & Lyko, F. (2008) · International Journal of Cancer · doi:10.1002/ijc.23607 · Cited by 949
Antiviral drugs in current clinical use
De Clercq, E. (2004) · Journal of Clinical Virology · doi:10.1016/j.jcv.2004.02.009 · Cited by 947
Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Majer, C. R., Sneeringer, C. J., Song, J., Johnston, L. D., Scott, M. P., Smith, J. J., Xiao, Y., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.009 · Cited by 923
Flow Chemistry: Recent Developments in the Synthesis of Pharmaceutical Products
Porta, R., Benaglia, M., & Puglisi, A. (2016) · Organic Process Research & Development · doi:10.1021/acs.oprd.5b00325 · Cited by 886
Action of 2',2'-difluorodeoxycytidine on DNA synthesis.
Huang, P., Chubb, S., Hertel, L. W., Grindey, G. B., & Plunkett, W. K. (1991) · PubMed · Cited by 876
MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L
Bernt, K. M., Zhu, N., Sinha, A. U., Vempati, S., Faber, J., Krivtsov, A. V., Feng, Z., Punt, N., Daigle, A., Bullinger, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.010 · Cited by 870
Cellular pharmacology of gemcitabine
Mini, E., Nobili, S., Caciagli, B., Landini, I., & Mazzei, T. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj941 · Cited by 842
HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase
Goldstone, D. C., Ennis-Adeniran, V., Hedden, J. J., Groom, H. C. T., Rice, G. I., Christodoulou, E., Walker, P. A., Kelly, G., Haire, L. F., Yap, M. W., et al. (2011) · Nature · doi:10.1038/nature10623 · Cited by 831
INTERACTIONS BETWEEN DEOXYRIBONUCLEOTIDE AND DNA SYNTHESIS
Reichard, P. (1988) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.57.070188.002025 · Cited by 779
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Basavapathruni, A., Jin, L., Boriack-Sjodin, P. A., Allain, C. J., Klaus, C. R., Raimondi, A., Scott, M. P., et al. (2013) · Blood · doi:10.1182/blood-2013-04-497644 · Cited by 722
The purine path to chemotherapy
Elion, G. B. (1989) · Science · doi:10.1126/science.2649979 · Cited by 687
Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).
Hertel, L. W., Boder, G. B., Kroin, J. S., Rinzel, S. M., Poore, G. A., Todd, G. C., & Grindey, G. B. (1990) · PubMed · Cited by 680
Walko, C. M., & Lindley, C. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.01.005 · Cited by 659
Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer
Parker, W. B. (2009) · Chemical Reviews · doi:10.1021/cr900028p · Cited by 622
Beutner, K. R., Friedman, D. J., Forszpaniak, C., Andersen, P. L., & Wood, M. J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.7.1546 · Cited by 613
The diverse functions of Dot1 and H3K79 methylation
Nguyen, A. T., & Zhang, Y. (2011) · Genes & Development · doi:10.1101/gad.2057811 · Cited by 597
Novel Process Windows for Enabling, Accelerating, and Uplifting Flow Chemistry
Hessel, V., Kralisch, D., Kockmann, N., Noël, T., & Wang, Q. (2013) · ChemSusChem · doi:10.1002/cssc.201200766 · Cited by 596
Mammalian deoxyribonucleoside kinases
Arnér, E. S. J., & Eriksson, S. (1995) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(95)00015-9 · Cited by 577
Extracellular adenosine triphosphate and adenosine in cancer
Stagg, J., & Smyth, M. J. (2010) · Oncogene · doi:10.1038/onc.2010.292 · Cited by 571
H3K79 Methylation Profiles Define Murine and Human MLL-AF4 Leukemias
Krivtsov, A. V., Feng, Z., Lemieux, M. E., Faber, J., Vempati, S., Sinha, A. U., Xia, X., Jesneck, J., Bracken, A. P., Silverman, L. B., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.10.001 · Cited by 550
THE SYNTHESIS OF 5-FLUOROPYRIMIDINES
Duschinsky, R., Pleven, E., & Heidelberger, C. (1957) · Journal of the American Chemical Society · doi:10.1021/ja01573a087 · Cited by 510
Nucleoside and nucleobase transport systems of mammalian cells
Griffith, D. A., & Jarvis, S. M. (1996) · Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes · doi:10.1016/s0304-4157(96)00008-1 · Cited by 493
2-Cyanoethyl Phosphate and its Use in the Synthesis of Phosphate Esters1
Tener, G. M. (1961) · Journal of the American Chemical Society · doi:10.1021/ja01462a032 · Cited by 491
Witkowski, J. T., Robins, R. K., Sidwell, R. W., & Simon, L. N. (1972) · Journal of Medicinal Chemistry · doi:10.1021/jm00281a014 · Cited by 471
Recent developments in adenosine receptor ligands and their potential as novel drugs
Müller, C. E., & Jacobson, K. A. (2011) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.12.017 · Cited by 431
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism
Peters, G. J., Backus, H. H. J., Freemantle, S., van Triest, B., Codacci-Pisanelli, G., van der Wilt, C. L., Smid, K., Lunec, J., Calvert, A. H., Marsh, S., et al. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(02)00082-0 · Cited by 420
5-Fluorouracil: Forty-Plus and Still Ticking. A Review of its Preclinical and Clinical Development
Grem, J. L. (2000) · Investigational New Drugs · doi:10.1023/a:1006416410198 · Cited by 417
Clinical pharmacology and pharmacogenetics of thiopurines
Sahasranaman, S., Howard, D., & Roy, S. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0478-6 · Cited by 405
Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.
Heinemann, V, Xu, Y. Z., Chubb, S., Sen, A., Hertel, L. W., Grindey, G. B., & Plunkett, W. (1990) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09518-5 · Cited by 399
Transport of Cyclic Nucleotides and Estradiol 17-β-d-Glucuronide by Multidrug Resistance Protein 4
Chen, Z.-S., Lee, K., & Kruh, G. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104833200 · Cited by 396
Gemcitabine: preclinical pharmacology and mechanisms of action.
Plunkett, W. K., Huang, P., Searcy, C. E., & Gandhi, V. V. (1996) · PubMed · Cited by 396
Arnaudeau, C., Lundin, C., & Helleday, T. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4564 · Cited by 386
Role of gemcitabine in cancer therapy
Toschi, L., Finocchiaro, G., Bartolini, S., Gioia, V, & Cappuzzo, F. (2005) · Future Oncology · doi:10.1517/14796694.1.1.7 · Cited by 373
Mechanism of action and selectivity of acyclovir
Elion, G. B. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90055-9 · Cited by 370
Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.
Abratt, R. P., Bezwoda, W. R., Falkson, G., Goedhals, L., Hacking, D., & Rugg, T. A. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.8.1535 · Cited by 359
Rosell, R., Danenberg, K. D., Alberola, V., Bepler, G., Sanchez, J. J., Camps, C., Provencio, M., Isla, D., Taron, M., Diz, P., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0156 · Cited by 352
Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL
Tzoneva, G., Perez-Garcia, A., Carpenter, Z., Khiabanian, H., Tosello, V., Allegretta, M., Paietta, E., Racevskis, J., Rowe, J. M., Tallman, M. S., et al. (2013) · Nature Medicine · doi:10.1038/nm.3078 · Cited by 350
Mesnil, M., & Yamasaki, H. (2000) · PubMed · Cited by 345
Powell, R. D., Holland, P. J., Hollis, T., & Perrino, F. W. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.c111.317628 · Cited by 344
The Pathogenesis of Mixed-Lineage Leukemia
Muntean, A. G., & Hess, J. L. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132434 · Cited by 344
9-(1,3-Dihydroxy-2-propoxymethyl)guanine: a new potent and selective antiherpes agent
Martin, J. C., Dvorak, C. A., Smee, D. F., Matthews, T. R., & Verheyden, J. P. H. (1983) · Journal of Medicinal Chemistry · doi:10.1021/jm00359a023 · Cited by 341
Bepler, G., Kusmartseva, I., Sharma, S., Gautam, A., Cantor, A., Sharma, A., & Simon, G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.1101 · Cited by 333
Ishikawa, T., Utoh, M., Sawada, N., Nishida, M., Fukase, Y., Sekiguchi, F., & Ishitsuka, H. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00682-5 · Cited by 325
Milhollen, M. A., Traore, T., Adams-Duffy, J., Thomas, M. P., Berger, A. J., Dang, L., Dick, L. R., Garnsey, J. J., Koenig, E., Langston, S. P., et al. (2010) · Blood · doi:10.1182/blood-2010-03-272567 · Cited by 323
Nilsen, H., Rosewell, I., Robins, P., Skjelbred, C. F., Andersen, S., Slupphaug, G., Daly, G., Krokan, H. E., Lindahl, T., & Barnes, D. E. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80271-3 · Cited by 320
DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer.
Gnyszka, A., Jastrzębski, Z., & Flis, S. (2013) · PubMed · Cited by 318
Damaraju, V. L., Damaraju, S., Young, J. D., Baldwin, S. A., Mackey, J., Sawyer, M. B., & Cass, C. E. (2003) · Oncogene · doi:10.1038/sj.onc.1206952 · Cited by 318
Hilden, J. M. (2006) · Blood · doi:10.1182/blood-2005-07-3011 · Cited by 309
Studies on Condensed Pyrimidine Systems. IX. The Synthesis of Some 6-Substituted Purines
Elion, G. B., Burgi, E., & Hitchings, G. H. (1952) · Journal of the American Chemical Society · doi:10.1021/ja01122a037 · Cited by 298
Chaparro, M., Ordás, I., Cabré, E., Garcia-Sanchez, V., Bastida, G., Peñalva, M., Gomollón, F., García-Planella, E., Merino, O., Gutiérrez, A., et al. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e318281f28f · Cited by 297
Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia
Meyer, J. A., Wang, J., Hogan, L. E., Yang, J. J., Dandekar, S., Patel, J. P., Tang, Z., Zumbo, P., Li, S., Zavadil, J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2558 · Cited by 297
Genini, D., Adachi, S., Chao, Q., Rose, D. W., Carrera, C. J., Cottam, H. B., Carson, D. A., & Leoni, L. M. (2000) · Blood · doi:10.1182/blood.v96.10.3537 · Cited by 290
5-Azacytidine, a new, highly effective cancerostatic
Šorm, F., Pískala, A., Čihák, A., & Veselý, J. (1964) · Experientia · doi:10.1007/bf02135399 · Cited by 286
The 5′-nucleotidases as regulators of nucleotide and drug metabolism
Hunsucker, S. A., Mitchell, B. S., & Spychala, J. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.01.003 · Cited by 284
Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors
Yu, W., Chory, E. J., Wernimont, A. K., Tempel, W., Scopton, A., Federation, A., Marineau, J. J., Qi, J., Barsyte-Lovejoy, D., Yi, J., et al. (2012) · Nature Communications · doi:10.1038/ncomms2304 · Cited by 281
Saunthararajah, Y., Hillery, C. A., Lavelle, D., Molokie, R., Dorn, L., Bressler, L., Gavazova, S., Chen, Y.-H., Hoffman, R., & DeSimone, J. (2003) · Blood · doi:10.1182/blood-2003-05-1738 · Cited by 277
Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes
Carson, D., Wasson, D., Taetle, R., & Yu, A. L.-T. (1983) · Blood · doi:10.1182/blood.v62.4.737.737 · Cited by 276
Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells
Ferry, K. V., Hamilton, T. C., & Johnson, S. W. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00441-x · Cited by 275
Studies on fluorinated pyrimidines. IV. Effects on nucleic acid metabolism in vivo.
DANNEBERG, P. B., MONTAG, B. J., & Heidelberger, C. (1958) · PubMed · Cited by 263
DNA building blocks: keeping control of manufacture
Hofer, A., Crona, M., Logan, D. T., & Sjöberg, B.-M. (2012) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2011.630372 · Cited by 260
Antiviral Lead Compounds from Marine Sponges
Sagar, S., Kaur, M., & Minneman, K. P. (2010) · Marine Drugs · doi:10.3390/md8102619 · Cited by 259
Discovery and development of clofarabine: a nucleoside analogue for treating cancer
Bonate, P. L., Arthaud, L., Cantrell, W. R., Stephenson, K., Secrist, J. A., & Weitman, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2055 · Cited by 257
Inhibition of Influenza Virus Ribonucleic Acid Polymerase by Ribavirin Triphosphate
Eriksson, B., Helgstrand, E., Johansson, N. G., Larsson, A., Misiorny, A., Noren, J. O., Philipson, L., Stenberg, K., Stening, G., Stridh, S., et al. (1977) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.11.6.946 · Cited by 257
2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines
Ruiz van Haperen, V. W. T., Veerman, G., Vermorken, J. B., & Peters, G. J. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90566-f · Cited by 253
Guo, Y., Kotova, E., Chen, Z.-S., Lee, K., Hopper-Borge, E., Belinsky, M. G., & Kruh, G. D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304059200 · Cited by 253
One-Third-the-Sites Transition-State Inhibitors for Purine Nucleoside Phosphorylase
Miles, R. W., Tyler, P. C., Furneaux, R. H., Bagdassarian, C. K., & Schramm, V. L. (1998) · Biochemistry · doi:10.1021/bi980658d · Cited by 246
Pratt, S., Shepard, R. L., Kandasamy, R. A., Johnston, P. A., Perry, W., & Dantzig, A. H. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0291 · Cited by 245
Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases
Van Rompay, A. R., Johansson, M., & Karlsson, A. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00048-6 · Cited by 244
Mechanisms of action of 6-thioguanine, 6-mercaptopurine, and 8-azaguanine.
Nelson, J. A., Carpenter, J. W., Rose, L. M., & Adamson, D. J. (1975) · PubMed · Cited by 243
Fukushima, M., Suzuki, N., Emura, T., Yano, S., Kazuno, H., Tada, Y., Yamada, Y., & Asao, T. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00253-7 · Cited by 239
The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs
Zhang, J., Visser, F., King, K. M., Baldwin, S. A., Young, J. D., & Cass, C. E. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9044-4 · Cited by 231
The fundamental role of epigenetics in hematopoietic malignancies
Galm, O., Herman, J. G., & Baylin, S. B. (2006) · Blood Reviews · doi:10.1016/j.blre.2005.01.006 · Cited by 230
Wiener klinische Wochenschrift
(2013) · Wiener klinische Wochenschrift · doi:10.1007/508.1613-7671 · Cited by 229
Woo, P. W. K., Dion, H. W., Lange, S., Dahl, L. F., & Durham, L. J. (1974) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.5570110438 · Cited by 227
Pharmacological and therapeutic effects of A3 adenosine receptor agonists
Fishman, P., Bar-Yehuda, S., Liang, B. T., & Jacobson, K. A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.10.007 · Cited by 227
The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy
Soucy, T. A., Dick, L. R., Smith, P. G., Milhollen, M. A., & Brownell, J. E. (2010) · Genes & Cancer · doi:10.1177/1947601910382898 · Cited by 225
Advances in the development of hybrid anticancer drugs
Fortin, S., & Bérubé, G. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.798296 · Cited by 223
Bianchi, V., & Spychala, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.r300032200 · Cited by 215
Anti-CD73 in Cancer Immunotherapy: Awakening New Opportunities
Antonioli, L., Yegutkin, G. G., Pacher, P., Blandizzi, C., & Haskó, G. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.01.003 · Cited by 213
Rich, T. A., Shepard, R. C., & Mosley, S. T. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.009 · Cited by 212
Cytosine Arabinoside Influx and Nucleoside Transport Sites in Acute Leukemia
Wiley, J. S., Jones, S. P., Sawyer, W. H., & Paterson, A. R. P. (1982) · Journal of Clinical Investigation · doi:10.1172/jci110472 · Cited by 212
García-Manteiga, J. M., Molina‐Arcas, M., Casado, F. J., Mazo, A., & Pastor‐Anglada, M. (2003) · PubMed · Cited by 211
The treatment of chronic progressive multiple sclerosis with cladribine.
Beutler, E., Sipe, J. C., Romine, J. S., Koziol, J. A., McMillan, R., & Zyroff, J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.4.1716 · Cited by 208
Parker, W. B., Shaddix, S. C., Chang, C., White, E. L., Rose, L. M., Brockman, R. W., Shortnacy, A. T., Montgomery, J. A. J., Secrist, J. A. I., & Bennett, L. L. (1991) · PubMed · Cited by 207
Topoisomerase IIα in chromosome instability and personalized cancer therapy
Chen, T., Sun, Y., Ji, P., Kopetz, S., & Zhang, W. (2015) · Oncogene · doi:10.1038/onc.2014.332 · Cited by 207
Takahashi, A., Imai, Y., Yamakoshi, K., Kuninaka, S., Ohtani, N., Yoshimoto, S., Hori, S., Tachibana, M., Anderton, E., Takeuchi, T., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2011.10.018 · Cited by 205
2-Substitution of N6-Benzyladenosine-5'-uronamides Enhances Selectivity for A3 Adenosine Receptors
Kim, H. O., Ji, X.-D., Siddiqi, S. M., Olah, M. E., Stiles, G. L., & Jacobson, K. A. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00047a018 · Cited by 202
Ribonucleotide reductases: radical enzymes with suicidal tendencies
Stubbe, J., & van der Donk, W. A. (1995) · Chemistry & Biology · doi:10.1016/1074-5521(95)90084-5 · Cited by 200
Roboz, G. J., Rosenblat, T., Arellano, M., Gobbi, M., Altman, J. K., Montesinos, P., O'Connell, C., Solomon, S. R., Pigneux, A., Vey, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.8562 · Cited by 198
REYES, P., & HEIDELBERGER, C. (1965) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)14702-0 · Cited by 198
Rutman, R. J., CANTAROW, A., & Paschkis, K. E. (1954) · PubMed · Cited by 196
Kicska, G. A., Long, L., Hörig, H., Fairchild, C., Tyler, P. C., Furneaux, R. H., Schramm, V. L., & Kaufman, H. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.071050798 · Cited by 192
DiMasi, J. A., & Paquette, C. (2004) · PharmacoEconomics · doi:10.2165/00019053-200422002-00002 · Cited by 189
Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation
Hatse, S., De Clercq, E., & Balzarini, J. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00035-0 · Cited by 189
Vora, A., Mitchell, C. D., Lennard, L., Eden, T., Kinsey, S. E., Lilleyman, J., & Richards, S. M. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69558-5 · Cited by 187
MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy
Nawrocki, S. T., Griffin, P., Kelly, K. R., & Carew, J. S. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.707192 · Cited by 186
Survival in Patients with Glioblastoma Receiving Valganciclovir
Söderberg-Nauclér, C., Rahbar, A., & Stragliotto, G. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1302145 · Cited by 183
Thiopurines, DNA damage, DNA repair and therapy-related cancer
Karran, P. (2006) · British Medical Bulletin · doi:10.1093/bmb/ldl020 · Cited by 182
Wielinga, P. R., Reid, G., Challa, E. E., van der Heijden, I., van Deemter, L., de Haas, M., Mol, C., Kuil, A. J., Groeneveld, E., Schuetz, J. D., et al. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.6.1321 · Cited by 179
Behrendt, R., Schumann, T., Gerbaulet, A., Nguyen, L. A., Schubert, N., Alexopoulou, D., Berka, U., Lienenklaus, S., Peschke, K., Sutter, K., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.07.037 · Cited by 179
Wohlhueter, R. M., McIvor, R. S., & Plagemann, P. G. W. (1980) · Journal of Cellular Physiology · doi:10.1002/jcp.1041040305 · Cited by 171
Nakamura, K., Yoshikawa, N., Yamaguchi, Y., et al. (2006) · PubMed · Cited by 167
Erion, M. D., Reddy, K. R., Boyer, S. H., Matelich, M. C., Gomez-Galeno, J., Lemus, R. H., Ugarkar, B. G., Colby, T. J., Schanzer, J., & van Poelje, P. D. (2004) · Journal of the American Chemical Society · doi:10.1021/ja031818y · Cited by 165
An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug
Ghoshal, K., & Jacob, S. T. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00040-3 · Cited by 164
Gemcitabine: Progress in the Treatment of Pancreatic Cancer
Heinemann, V. (2001) · Oncology · doi:10.1159/000055290 · Cited by 164
Cordycepin Inhibits Protein Synthesis and Cell Adhesion through Effects on Signal Transduction
Wong, Y. Y., Moon, A., Duffin, R., Barthet-Barateig, A., Meijer, H. A., Clemens, M. J., & de Moor, C. H. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.071159 · Cited by 163
Mechanism of allosteric activation of SAMHD1 by dGTP
Ji, X., Wu, Y., Yan, J., Mehrens, J., Yang, H., DeLucia, M., Hao, C., Gronenborn, A. M., Skowronski, J., Ahn, J., et al. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2692 · Cited by 161
DNA Methyltransferase-1 Inhibitors as Epigenetic Therapy for Cancer
Singh, V., Sharma, P., & Capalash, N. (2013) · Current Cancer Drug Targets · doi:10.2174/15680096113139990077 · Cited by 161
Understanding Ribonucleotide Reductase Inactivation by Gemcitabine
Cerqueira, N. M. F. S. A., Fernandes, P. A., & Ramos, M. J. (2007) · Chemistry - A European Journal · doi:10.1002/chem.200700260 · Cited by 161
Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?
Borden, K. L. B., & Čuljković, B. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.496506 · Cited by 159
Zhao, Y., Xiong, X., Jia, L., & Sun, Y. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.125 · Cited by 158
Carson, D. A., Wasson, D. B., Esparza, L. M., Carrera, C. J., Kipps, T. J., & Cottam, H. B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.2970 · Cited by 158
Gilbert, J. A., Salavaggione, O. E., Ji, Y., Pelleymounter, L. L., Eckloff, B. W., Wieben, E. D., Ames, M. M., & Weinshilboum, R. M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1969 · Cited by 158
Robak, T., Lech‐Marańda, E., Korycka, A., et al. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706778742918 · Cited by 154
Ślusarczyk, M., Lopez, M. H., Balzarini, J. M., Mason, M. D., Jiang, W. G., Blagden, S. P., Thompson, E., Ghazaly, E. A., & McGuigan, C. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401853a · Cited by 153
Long‐Term Effectiveness Of The Burch Colposuspension In Female Urinary Stress Incontinence
Eriksen, B. C., Hagen, B., Eik‐Nes, S. H., Molne, K., Mjølnererd, O. K., & Romslo, L. (1990) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.3109/00016349009021038 · Cited by 151
Hubeek, I., Stam, R. W., Peters, G. J., Broekhuizen, R., Meijerink, J. P. P., van Wering, E. R., Gibson, B. E. S., Creutzig, U., Zwaan, C. M., Cloos, J. J., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602881 · Cited by 150
Achanta, G., Pelicano, H., Feng, L., Plunkett, W. K., & Huang, P. (2001) · PubMed · Cited by 148
Parker, W. B., Bapat, A. R., Shen, J. X., Townsend, A. J., & Cheng, Y. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09779-2 · Cited by 145
Sundaram, M., Yao, S. Y. M., Ingram, J. C., Berry, Z. A., Abidi, F., Cass, C. E., Baldwin, S. A., & Young, J. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107169200 · Cited by 143
Ritzel, M. W. L., Ng, A. M. L., Yao, S. Y. M., Graham, K., Loewen, S. K., Smith, K. M., Hyde, R. J., Karpinski, E., Cass, C. E., Baldwin, S. A., et al. (2001) · Molecular Membrane Biology · doi:10.1080/09687680118530 · Cited by 141
Pettersson, F., Yau, C. S. F., Dobocan, M. C., Čuljković, B., Retrouvay, H., Puckett, R., Flores, L. M., Krop, I. E., Rousseau, C., Cocolakis, E., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2334 · Cited by 141
Cook, A. F., Holman, M. J., KRAMER, M. J., & Trown, P. W. (1979) · Journal of Medicinal Chemistry · doi:10.1021/jm00197a010 · Cited by 140
Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome
Qin, T., Castoro, R. J., Ahdab, S. E., Jelı́nek, J., Wang, X., Si, J., Shu, J., He, R. L., Zhang, N., Chung, W., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023372 · Cited by 139
Sengupta, T. K., Leclerc, G. M., Kinser, T. T. H., Leclerc, G. J., Singh, I., & Barredo, J. C. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-46 · Cited by 137
Effect of 5-aza-2'-deoxycytidine against leukemic and hemopoietic tissues in AKR mice.
Šorm, F., & Veselý, J. (1968) · PubMed · Cited by 134
Xie, K. C., & Plunkett, W. K. (1996) · PubMed · Cited by 133
Fishman, P. (1992) · International Journal of Oncology · doi:10.3892/ijo_00000008 · Cited by 132
Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors.
KONO, A., Hara, Y., SUGATA, S., Karube, Y., Matsushima, Y., & Ishitsuka, H. (1983) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.31.175 · Cited by 131
Thiopurine biology and pharmacology
Aarbakke, J., Janka-Schaub, G. E., & Elion, G. B. (1997) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(96)01007-3 · Cited by 131
Hsu, C., Shen, Y., Lin, Z.-Z., Chen, P.-J., Shao, Y.-Y., Ding, Y.-H., Hsu, C., & Cheng, A.-L. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.01.035 · Cited by 130
Gemcitabine: A pharmacologic and clinical overview
Barton‐Burke, M. (1999) · Cancer Nursing · doi:10.1097/00002820-199904000-00011 · Cited by 130
Regulation of deoxynucleotide metabolism in cancer: novel mechanisms and therapeutic implications
Kohnken, R. A., Kodigepalli, K. M., & Wu, L. J. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0446-6 · Cited by 130
ABC transporters and their role in nucleoside and nucleotide drug resistance
Fukuda, Y., & Schuetz, J. D. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.042 · Cited by 129
Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD
de Boer, N. K. H., Bodegraven, A. A. V., Jharap, B., de Graaf, P., & Mulder, C. J. J. (2007) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep1000 · Cited by 128
Heterozygous colon cancer-associated mutations of SAMHD1 have functional significance
Rentoft, M., Lindell, K., Tran, P., Chabes, A. L., Buckland, R. J., Watt, D. L., Marjavaara, L., Nilsson, A. K., Melin, B. S., Trygg, J., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1519128113 · Cited by 128
Myelodysplastic syndromes: 2014 update on diagnosis, risk‐stratification, and management
Garcia‐Manero, G. (2014) · American Journal of Hematology · doi:10.1002/ajh.23642 · Cited by 127
Hagmann, W., Jesnowski, R., & Löhr, M. J. (2010) · Neoplasia · doi:10.1593/neo.10576 · Cited by 126
Ciliberto, D., Botta, C., Correale, P., Rossi, M., Caraglia, M., Tassone, P., & Tagliaferri, P. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.08.019 · Cited by 125
MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia
Ferracin, M., Zagatti, B., Rizzotto, L., Cavazzini, F., Veronese, A., Ciccone, M., Saccenti, E., Lupini, L., Grilli, A., Angeli, C. D., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-123 · Cited by 125
Coleman, L., Peter, M. B., Teall, T. J., Brannan, R. A., Hanby, A. M., Honarpisheh, H., Shaaban, A. M., Smith, L., Speirs, V., Verghese, E. T., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605044 · Cited by 122
Epigenomes as therapeutic targets
Hamm, C. A., & Costa, F. F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.03.003 · Cited by 122
Targeting the RNA Splicing Machinery as a Novel Treatment Strategy for Pancreatic Carcinoma
Hayes, G. M., Carrigan, P. E., Beck, A. M., & Miller, L. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4065 · Cited by 121
Emura, T., Suzuki, N., Yamaguchi, M., Ohshimo, H., & Fukushima, M. (2004) · International Journal of Oncology · doi:10.3892/ijo.25.3.571 · Cited by 120
McGuigan, C., Murziani, P. G. S., Ślusarczyk, M., Gönczy, B., Voorde, J. V., Liekens, S., & Balzarini, J. M. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200815w · Cited by 118
Thionations Using a P4S10−Pyridine Complex in Solvents Such as Acetonitrile and Dimethyl Sulfone
Bergman, J., Pettersson, B., Hasimbegovic, V., & Svensson, P. H. (2011) · The Journal of Organic Chemistry · doi:10.1021/jo101865y · Cited by 118
A Novel Action of Human Apurinic/Apyrimidinic Endonuclease
Chou, K.-M., Kukhanova, M. K., & Cheng, Y. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004082200 · Cited by 117
Nawrocki, S. T., Kelly, K. R., Smith, P. G., Espitia, C. M., Possemato, A. P., Beausoleil, S. A., Milhollen, M. A., Blakemore, S. J., Thomas, M., Berger, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3212 · Cited by 117
Cordycepin protects against cerebral ischemia/reperfusion injury in vivo and in vitro
Cheng, Z., He, W., Zhou, X., Lv, Q., Xu, X., Yang, S., Zhao, C., & Guo, L. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.04.052 · Cited by 116
DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells
Saiki, Y., Yoshino, Y., Fujimura, H., Manabe, T., Kudo, Y., Shimada, M., Mano, N., Nakano, T., Lee, Y., Shimizu, S., et al. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.03.122 · Cited by 114
ffski, P. S. (2004) · Anti-Cancer Drugs · doi:10.1097/00001813-200402000-00001 · Cited by 114
Azacytidine (Vidaza�) in the treatment of myelodysplastic syndromes
Raj, K. K., & Mufti, G. J. (2006) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.2006.2.4.377 · Cited by 113
The oral fluoropyrimidines in cancer chemotherapy.
Lamont, E. B., & Schilsky, R. L. (1999) · PubMed · Cited by 113
Fang, P., Hu, J., Cheng, Z., Liu, Z., Wang, J., & Jiao, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049717 · Cited by 112
Temmink, O. H., Emura, T., de Bruin, M., Fukushima, M., & Peters, G. J. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00477.x · Cited by 110
Santi, D. V., & Hardy, L. W. (1987) · Biochemistry · doi:10.1021/bi00400a016 · Cited by 109
Wei, X., Wang, W., Wang, L., Zhang, Y., Zhang, X., Chen, M., Wang, F., Yu, J., Ma, Y., & Sun, G. (2016) · Cancer Medicine · doi:10.1002/cam4.626 · Cited by 109
A comparative overview of general risk factors associated with the incidence of colorectal cancer
Rasool, S., Kadla, S. A., Rasool, V., & Ganai, B. A. (2013) · Tumor Biology · doi:10.1007/s13277-013-0876-y · Cited by 108
Synthesis, Crystallization, and Biological Evaluation of an Orally Active Prodrug of Gemcitabine
Bender, D. M., Bao, J., Dantzig, A. H., Diseroad, W. D., Law, K. L., Magnus, N. A., Peterson, J. A., Perkins, E. J., Pu, Y. J., Reutzel‐Edens, S. M., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901181h · Cited by 107
Xie, C., & Plunkett, W. K. (1995) · PubMed · Cited by 107
5-Fluorouracil Derivatives. I. The Synthesis of 1-Carbamoyl-5-fluorouracils
Ozaki, S., Ike, Y., Mizuno, H., Ishikawa, K., & Mori, H. (1977) · Bulletin of the Chemical Society of Japan · doi:10.1246/bcsj.50.2406 · Cited by 105
Vorbrüggen, H., & Ruh‐Pohlenz, C. (1999) · Organic reactions · doi:10.1002/0471264180.or055.01 · Cited by 104
Targeting the PI3K/AKT/mTOR Pathway: Biomarkers of Success and Tribulation
Owonikoko, T. K., & Khuri, F. R. (2013) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbook_am.2013.33.e395 · Cited by 104
Mader, R. M., Müller, M., & Steger, G. G. (1998) · General Pharmacology The Vascular System · doi:10.1016/s0306-3623(98)00191-8 · Cited by 104
Blank, J. L., Liu, X. J., Cosmopoulos, K., Bouck, D. C., Garcia, K., Bernard, H., Tayber, O., Hather, G., Liu, R., Narayanan, U., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1729 · Cited by 104
Pratt, S. E., Durland–Busbice, S., Shepard, R. L., Heinz-Taheny, K. M., Iversen, P. W., & Dantzig, A. H. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1184 · Cited by 104
Grunebaum, E., Cohen, A., & Roifman, C. M. (2013) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000006 · Cited by 104
Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management
Pardanani, A. D. (2013) · American Journal of Hematology · doi:10.1002/ajh.23459 · Cited by 103
Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine
Lavelle, D., Vaitkus, K., Ling, Y., Ruiz, M. A., Mahfouz, R. Z., Ng, K. P., Negrotto, S., Smith, N. F., Terse, P., Engelke, K. J., et al. (2011) · Blood · doi:10.1182/blood-2011-08-371690 · Cited by 103
Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours
Doi, T., Ohtsu, A., Yoshino, T., Boku, N., Onozawa, Y., Fukutomi, A., Hironaka, S., Koizumi, W., & Sasaki, T. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.274 · Cited by 102
High-performance Liquid Chromatographic Analysis of Chemical Stability of 5-aza-2′-Deoxycytidine
Lin, K.-T., Momparlerm, R. L., & Rivard, G. E. (1981) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600701112 · Cited by 102
Bouchard, J., & Momparler, R. L. (1983) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)14371-x · Cited by 102
Murakami, Y., Kazuno, H., Emura, T., Tsujimoto, H., Suzuki, N., & Fukushima, M. (2000) · International Journal of Oncology · doi:10.3892/ijo.17.2.277 · Cited by 101
Accessing New Chemical Entities through Microfluidic Systems
Rodrigues, T., Schneider, P., & Schneider, G. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201400988 · Cited by 101
Chang, F.-M., Reyna, S. M., Granados, J. C., Wei, S., Innis‐Whitehouse, W., Maffi, S. K., Rodriguez, E., Slaga, T. J., & Short, J. D. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.397703 · Cited by 101
Synthesis of a 2-deoxy-D-ribofuranosyl-5-azacytosine
Pliml, J., & Šorm, F. (1964) · Collection of Czechoslovak Chemical Communications · doi:10.1135/cccc19642576 · Cited by 101
Takenaka, K., Morgan, J. A., Scheffer, G. L., Adachi, M., Stewart, C. F., Sun, D., Leggas, M. L., Ejendal, K. F. K., Hrycyna, C. A., & Schuetz, J. D. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4720 · Cited by 100
Zhang, X., Chen, Y., Hao, L., Hou, A., Chen, X., Li, Y., Wang, R., Luo, P., Ruan, Z., Ou, J., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.08.004 · Cited by 99
Incorporation of 6‐Thioguanosine and 4‐Thiouridine into RNA
Melvin, W. T., MILNE, H. B., Slater, A. A., Allen, H., & KEIR, H. M. (1978) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1978.tb12756.x · Cited by 97
Phosphorylation of Pyrimidine Deoxynucleoside Analog Diphosphates
Krishnan, P., Fu, Q., Lam, W., Liou, J.-Y., Dutschman, G. E., & Cheng, Y. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109025200 · Cited by 97
Lalibert�, J., Márquez, V. E., & Momparler, R. L. (1992) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686478 · Cited by 97
The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer
Fang, F., Munck, J. M., Tang, J., Taverna, P., Wang, Y., Miller, D. F., Pilrose, J. M., Choy, G. S., Azab, M., Pawelczak, K. S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1553 · Cited by 97
Houédé, N., & Pourquier, P. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.06.004 · Cited by 97
Bergman, A. M., Adema, A. D., Balzarini, J. M., Bruheim, S., Fichtner, I., Noordhuis, P., Fodstad, Ø., Myhren, F., Sandvold, M. L., Hendriks, H. R., et al. (2010) · Investigational New Drugs · doi:10.1007/s10637-009-9377-7 · Cited by 96
Cited by
Challenges and Opportunities in Cancer Drug Resistance
Ward, R. A., Fawell, S., Floc’h, N., Flemington, V., McKerrecher, D., & Smith, P. D. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00383 · Cited by 445
Urea Derivatives in Modern Drug Discovery and Medicinal Chemistry
Ghosh, A. K., & Brindisi, M. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01541 · Cited by 401
Carbohydrate-based drugs launched during 2000−2021
Cao, X., Du, X., Jiao, H., An, Q., Chen, R., Fang, P., Wang, J., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.020 · Cited by 267
Metadata
- Authors
- Shelton, J., Lu, X., Hollenbaugh, J. A., Cho, J. H., Amblard, F., & Schinazi, R. F.
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-11-23
- Volume
- 116
- Issue
- 23
- Pages
- 14379-14455
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- OpenAlex
- W2549858084
- Cited by
- 409
- References
- 402
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.